Illumina's up-and-coming constellation innovation delivers accuracy, speed, and ease of use in trial by GeneDx Constellation outperformed orthogonal methods in...
SAN FRANCISCO, Oct. 15, 2025 /PRNewswire/ -- Quintara Biosciences today announced that it has completed the acquisition of Laragen Sanger...
LONDON, ON, Oct. 15, 2025 /PRNewswire/ - EpiSign Inc. today announced the launch of METRIC, a next-generation software platform that...
EHRCON25, openEHR's flagship global conference on electronic health record innovation, will gather health IT leaders from across South America, Africa,...
BOSTON and LONDON, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) (the “Company”), an oncology biotechnology company...
The acquisition strengthens Trinity's interdisciplinary team of science advisers experienced in evaluating human health risks from chemical, physical and biological...
PISCATAWAY, N.J., Oct. 14, 2025 /PRNewswire/ -- Sampled, a fully integrated analytical laboratory and biorepository, has partnered with AutoGen to...
Internal Promotion Supports Ongoing Business Refocusing Efforts with Established Financial Operations Expertise HALLANDALE BEACH, Fla., Oct. 14, 2025 /PRNewswire/ --...
Findings complement previously announced results in triple-negative breast cancer (TNBC) and prostate cancer models, highlighting Telomir-1's consistent impact on cancer...
Prestigious European Society for Medical Oncology Conference “trials-in-progress” session Pivotal OVATION 3 trial of its DNA-mediated immunotherapy in newly diagnosed...
EMERYVILLE, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage...
42% reduction in mean intraocular pressure (IOP) compared to baseline (p<0.0001)100% of patients were off all topical IOP-lowering medications at...
Appoints Shawn Matthews, CEO of DNA Holdings Venture, Inc., and Former CEO of Cantor Fitzgerald, to its Board of Directors...
DOYLESTOWN, Pa., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical...
Notification has no immediate effect on the Company’s listing or day-to-day operationsROSELAND, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Milestone...
Greater than 90% depletion of B cells within 12 hours of a single dose of AAN-14xMultiple redosing of AAN-14x at...
– Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst’s HAE...
Presentation will cover two-year clinical efficacy, immunogenicity and safety dataData will be presented at an oral session on October 17,...
Cystic Fibrosis Foundation to provide up to $11 million in additional funding to accelerate development of 4D-710 for cystic fibrosis,...
Appointment adds three decades of financial and operational leadership to Soleno’s BoardREDWOOD CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) --...